Nebulizer maker Aerogen and inhaled interferon developer Synairgen have entered a strategic partnership for development of a custom device for delivery of Synairgen’s SNG001 inhaled interferon-beta, the companies have announced, noting that the new agreement “builds on a long-standing relationship.”
A Phase 2 trial of SNG001 in patients with viral respiratory infections who are on mechanical ventilation was initiated recently and, according to the announcement, “The partnership with Aerogen seeks to ensure that SNG001 is delivered using a proven, hospital-trusted technology, optimising drug delivery and patient outcomes.” In addition to the Phase 2 INVENT study that is underway, Synairgen has previously conducted clinical trials of SNG001 for the treatment of COVID-19, COPD, and asthma.
Synairgen CEO Joseph Colliver commented, “Pairing SNG001 with Aerogen’s advanced aerosol technology is a vital step in our mission to improve outcomes for critically ill respiratory patients. Aerogen’s track record and technical leadership give us confidence that together, we can advance the development and delivery of this much-needed therapy. Moreover, the manufacturing, supply and exclusivity terms in our agreement are important for the future commercialization of the product”.
Aerogen CEO John Power said, “By uniting our technology to address the significant challenge of delivering biologics to the lungs of patients in an intensive care setting with Synairgen’s cutting-edge potential therapeutic, we aim to accelerate the development of a much-needed inhaled treatment for critically ill respiratory patients.”
Read the Aerogen and Synairgen press release
